ABIVAX Societe Anonyme ABVX.PA · Stock Open ABIVAX Societe Anonyme in new tab
ABIVAX Societe Anonyme Analysis (ABVX.PA)
Is ABIVAX Societe Anonyme a good investment? ABIVAX Societe Anonyme (ABVX.PA) is currently trading at 99.95 EUR. Market analysts have a consensus price target of 138.97 EUR. This suggests a potential upside from current levels.
Earnings Schedule: ABIVAX Societe Anonyme is expected to release its next earnings report on Sept. 21, 2026. The market consensus estimate for Forward EPS is -2.66.
Investor FAQ
Does ABIVAX Societe Anonyme pay a dividend?
No, it does not currently pay a dividend.
What asset class is ABIVAX Societe Anonyme?
ABIVAX Societe Anonyme is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Sept. 21, 2026. The company currently has a trailing EPS of -4.61.
Company Profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Community Discussion